Recent advances in myorelaxant therapy.
Meakin
G H
GH
University Department of Anaesthesia, Royal Manchester Children's Hospital, Pendlebury, Manchester, UK.
D000732:Androstanols / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D001279:Atracurium / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics*; D002648:Child; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007223:Infant; D007546:Isoquinolines / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D000077590:Mivacurium; D009132:Muscles / Q000187:drug effects / Q000378:metabolism; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D000077123:Rocuronium; D014673:Vecuronium Bromide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics*
D000732:Androstanols; D007546:Isoquinolines; D009466:Neuromuscular Blocking Agents; D003473:Neuromuscular Nondepolarizing Agents; D001279:Atracurium; D000077590:Mivacurium; D014673:Vecuronium Bromide; C082938:rapacuronium; C101584:cisatracurium; D000077123:Rocuronium